Key result
Colchicine and canakinumab show potential as novel AF therapies by targeting the NLRP3 inflammasome.
Why the study?
NLRP3 inflammasome signaling has been implicated in AF pathophysiology, but its precise role in various cardiac cell types remains poorly understood.
Do therapeutics targeting the NLRP3 inflammasome improve the management of atrial fibrillation?
Do therapeutics targeting the NLRP3 inflammasome improve the management of atrial fibrillation?
Targeting the NLRP3 inflammasome with agents like colchicine or canakinumab represents a potential novel therapeutic strategy for the management of atrial fibrillation.
Answers are grounded in this paper and cite their sources.
May support NLRP3 inhibition as an AF strategy; leaves open confirmation in prospective trials.
Inflammatory signalling via the nod-like receptor (NLR) family pyrin domain-containing protein-3 (NLRP3) inflammasome has recently been implicated in the pathophysiology of atrial fibrillation (AF). However, the precise role of the NLRP3 inflammasome in various cardiac cell types is poorly understood. Targeting components or products of the inflammasome and preventing their proinflammatory consequences may constitute novel therapeutic treatment strategies for AF. In this review, we summarise the current understanding of the role of the inflammasome in AF pathogenesis. We first review the NLRP3 inflammasome pathway and inflammatory signalling in cardiomyocytes, (myo)fibroblasts and immune cells, such as neutrophils, macrophages and monocytes. Because numerous compounds targeting NLRP3 signalling are currently in preclinical development, or undergoing clinical evaluation for other indications than AF, we subsequently review known therapeutics, such as colchicine and canakinumab, targeting the NLRP3 inflammasome and evaluate their potential for treating AF.
No takes yet. Share an insight, caveat, or question.
Niskala et al. (2024) conducted a review in Atrial fibrillation. NLRP3 inflammasome targeted therapies (e.g., colchicine, canakinumab) was evaluated. Targeting the NLRP3 inflammasome with therapeutics such as colchicine and canakinumab may constitute a novel treatment strategy for the management of atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: